Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

(NY: BLCO )

16.42 +0.45 (+2.82%)
Official Closing Price Updated: 7:00 PM EDT, Mar 21, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 218,042
Open 16.07
Bid (Size) 15.74 (1)
Ask (Size) 17.41 (1)
Prev. Close 15.97
Today's Range 15.99 - 16.52
52wk Range 12.20 - 20.20
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Benzinga's Top Ratings Upgrades, Downgrades For March 9, 2023
 
Via Benzinga
The Latest Analyst Ratings for Bausch & Lomb
 
Via Benzinga

Performance

YTD
+4.45%
+4.45%
1 Month
-11.39%
-11.39%
3 Month
+12.93%
+12.93%
6 Month
-3.35%
-3.35%
1 Year
-17.90%
-17.90%

More News

Read More
Bausch + Lomb Announces Fourth-Quarter and Full-Year 2022 Results
From Bausch + Lomb Corporation
Via Business Wire
Trade Desk, Roblox, Herbalife And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
7 Analysts Have This to Say About Bausch & Lomb
Via Benzinga
What 7 Analyst Ratings Have To Say About Bausch & Lomb
Via Benzinga
Expert Ratings for Bausch & Lomb
Via Benzinga
Bausch + Lomb Appoints Brent Saunders as Chief Executive Officer and Chair of the Board of Directors, Effective March 6, 2023
From Bausch + Lomb Corporation
Via Business Wire
New Bausch + Lomb Social Media Campaign Highlights What ‘Sights’ Inspire AMD Patients
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb and Modulight Announce FDA Approval of ML6710i Photodynamic Laser for Use with Bausch + Lomb’s VISUDYNE® (Verteporfin for Injection)
From Bausch + Lomb Corporation
Via Business Wire
What 4 Analyst Ratings Have To Say About Bausch & Lomb
Via Benzinga
What 4 Analyst Ratings Have To Say About Bausch & Lomb
Via Benzinga
Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2022 Financial Results on February 22
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Acquires AcuFocus, Inc.
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Introduces Enhanced PreserVision® AREDS 2 Formula Mini Soft Gels with OCUSorb™
From Bausch + Lomb Corporation
Via Business Wire
Expert Ratings for Bausch & Lomb
Via Benzinga
Bausch + Lomb Publishes Update Presentation for the 41st Annual J.P. Morgan Healthcare Conference
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Announces Participation at the 41st Annual J.P. Morgan Healthcare Conference
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb and Novaliq Announce Publication of Pivotal Phase 3 Data on NOV03 (Perfluorohexyloctane) in Ophthalmology
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb and Glaucoma Research Foundation Announce Launch of Screen, Protect, Cure Campaign In Recognition of Glaucoma Awareness Month
From Bausch + Lomb Corporation
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For December 21, 2022
Via Benzinga
Battered FTX's CEO Sam Bankman-Fried Arrested, Elon Musk's SpaceX Mammoth Valuation Of $140B, China Weighs Over $143B In Semiconductor Push: Top Stories Tuesday, Dec. 13
Via Benzinga
Bausch Health Investors Request Blocking Eye-Care Business Spinoff, Alleging Protection From Lawsuits
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 12, 2022
Via Benzinga
From Corporate Raider To Activist Investor: Here Are Three High-Yielding Stocks Carl Icahn Favors
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.